Circle Pharma Advances with CID-078 Clinical Trial
Circle Pharma, Inc., a clinical-stage biopharmaceutical company, specializes in pioneering macrocycle therapies. Recently, they announced a significant milestone—the first patient cohort was dosed in Phase 1 clinical trials of their innovative oral cyclin A/B RxL inhibitor, CID-078. This trial will explore the drug's efficacy in treating patients with advanced solid tumors, especially those with heightened E2F transcription factor activity. Targeted cancers include small cell lung cancer and various types of breast cancer.
Trial Overview and Expectations
David J. Earp, JD, Ph.D., the CEO of Circle Pharma, expressed enthusiasm about the Investigational New Drug (IND) application for CID-078 being approved. He revealed that this approval has allowed the compound to transition into human trials at esteemed cancer centers. These trials aim to gather critical clinical proof-of-concept data, assessing CID-078’s potential to address substantial medical needs.
CID-078 works by selectively inhibiting essential protein interactions between cyclins A and B, both crucial for cancer cell growth and survival. This approach is based on groundbreaking research by Nobel Laureate William G. Kaelin Jr., MD, who explored the concept of synthetic lethality concerning cyclin disruptions. By targeting these pathways, Circle Pharma hopes to offer new hope to patients suffering from resistant cancers.
Insights from Experts
The opinion of Geoffrey Shapiro, MD, Ph.D., from the Dana-Farber Cancer Institute, adds credibility to the urgent need for CID-078. He highlighted the significance of targeting E2F-driven cancer cells and emphasized the lack of selective therapeutic agents until now. The anticipation surrounding Circle Pharma’s progress into clinical settings illustrates the excitement within the cancer research community.
Clinical Trial Design
The Phase 1 trial (NCT06577987) is designed as an open-label, multi-center study, aiming to recruit up to 100 patients. Investigators will assess the safety, pharmacokinetics, and preliminary anti-tumor efficacy of CID-078 across various solid tumors. According to Circle Pharma, initial findings on safety and anti-tumor activity are expected to be disclosed in the near future.
About CID-078
CID-078 represents a groundbreaking investigational therapy specifically formulated to be orally bioavailable. This agent is envisioned to precisely target tumor cells with oncogenic changes leading to cell cycle dysregulation. Earlier studies have supported the potential of these cyclin inhibitors in achieving significant tumor regression in preclinical models, establishing a strong rationale for advancing CID-078 into further clinical assessments.
Circle Pharma's Vision
Circle Pharma is not merely focusing on short-term goals; they are committed to redefining therapeutic possibilities for patients. Based in South San Francisco, the company’s innovative MXMO™ platform integrates structure-based drug design with advanced synthetic chemistry. This unique approach aims to develop macrocycle therapies that are not only effective but also accessible through various administration routes, including oral intake.
Moreover, their focus is primarily on targeting cyclins, which play a pivotal role in regulating cell cycle progression—a crucial factor in many cancer types. The dedication to unearthing transformative treatments illustrates Circle Pharma's commitment to addressing unmet medical needs in oncology.
Frequently Asked Questions
What is CID-078?
CID-078 is a first-in-class oral cyclin A/B RxL inhibitor developed by Circle Pharma, targeting advanced solid tumors.
What types of cancer is CID-078 being tested on?
The clinical trial focuses on cancers such as small cell lung cancer and specific breast cancer types like triple-negative and ER+ HER-2- breast cancer.
How many patients will be enrolled in the trial?
Up to 100 patients are expected to be enrolled in the open-label Phase 1 clinical trial.
What are the goals of the Phase 1 trial?
The trial aims to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of CID-078.
When are preliminary results expected to be released?
Circle Pharma anticipates reporting preliminary safety and anti-tumor activity data from the trial in the future.
